SGO Practice Guidelines: Introductory Remarks

OncologyONCOLOGY Vol 11 No 7
Volume 11
Issue 7

Thousands of practice guidelines/practice parameters have been published by various professional organizations. The American Medical Association,[1] American College of Physicians,[2,3] and others[4-6] have written extensively about

Thousands of practice guidelines/practice parameters have been publishedby various professional organizations. The American Medical Association,[1]American College of Physicians,[2,3] and others[4-6] have written extensivelyabout methodologic, quality, and cost considerations in relation to suchguidelines. In the early 1990s, the Society of Surgical Oncology participatedin the development of extensive evidence-based standards of care for breastconservation treatment of primary breast cancer patients.[7]

More recently, the Society undertook a more ambitious initiative aimedat developing surgical practice guidelines directed toward the evaluationand initial management of patients with signs and symptoms cancer. Theseguidelines encompass the major cancer sites.

Scope and Format of the Guidelines

The Society of Surgical Oncology practice guidelines were based on detailedreview by nationally recognized experts in their respective fields. Eachguideline represents a consensus of multiple members of the Society ofSurgical Oncology who are well known for their expertise. The authors havestressed the symptoms and signs of primary cancer without discussing screeningprograms. The guidelines also discuss the timely evaluation of the symptomaticpatient, appropriate preoperative evaluation for extent of disease, andthe role of the surgeon in the diagnosis and treatment of cancer.

Separate sections on adjuvant therapy, follow-up programs, or managementof recurrent cancer have been intentionally omitted. For many sites, perioperativeadjuvant combined-modality therapy has been shown to improve outcomes.Where appropriate, such therapy is discussed under surgical management.

The guidelines are presented in minimal outline form as a delineationof therapeutic options. It is not the intent of these guidelines to definein detail all of the alternatives, risks, and outcomes for surgical orcombined-modality therapy of the cancer patient. For most sites, the generallyacceptable therapeutic options are defined.

Following each guideline is a brief narrative highlighting and expandingon selected sections of the guideline document, with a few relevant references.The current staging system for the site and approximate 5-year survivaldata are also included.


1 Attributes to Guide the Development of Practice Parameters. Chicago,Office of Quality Assurance and Medical Review, American Medical Association,1993.

2. Farmer RG ,White LJ: Medical quality assessment and the AmericanCollege of Physicians. J Am Coll Cardiol 14:69A-71A, 1989.

3. Ball JR. Practice guidelines and their role in quality assuranceand cost effectiveness. Qual Assur Health Care 2:31-36, 1990.

4. Phelps CE: The methodologic foundation of studies of the appropriatenessof medical care. N Engl J Med 329:1241-1245, 1993.

5. McDonald CJ, Overhage JM: Guidelines you can follow and can trust:An ideal and an example (editorial). JAMA 271,:872-873, 1994.

6. Browman GP, Levine MN, Mohide EA, et al: The practice guidelinesdevelopment cycle: A conceptual for practice guidelines development andimplementation. J Clin Oncol 13:502-512, 1995.

7. Winchester DP, Cox JD, for the American College of Radiology, AmericanCollege of Surgeons, College of American Pathologists, and Society of SurgicalOncology: Standards for breast-conservation treatment. CA Cancer J Clin42:134-162, 1992.

Related Videos
Experts on multiple myeloma
Sara M. Tolaney, MD, MPH, discusses how, compared with antibody-drug conjugates, chemotherapy produces low response rates and disease control in the treatment of those with hormone receptor–positive, HER2-negative metastatic breast cancer.
Experts on multiple myeloma
Hope Rugo, MD, speaks to the importance of identifying patients with aromatase inhibitor–resistant, hormone receptor–positive, HER2-negative advanced breast cancer who are undergoing treatment with capivasertib/fulvestrant who may be at a high risk of developing diabetes or hyperglycemia.
Sara M. Tolaney, MD, MPH, describes the benefit of sacituzumab govitecan for patients with HER2-low metastatic breast cancer seen in the final overall survival analysis of the phase 3 TROPiCS-02 study.
Experts on MM
Experts on colorectal cancer
Experts on MM
An expert from Vanderbilt University Medical Center says that patients with relapsed/refractory multiple myeloma may be able to live a normal life following response to salvage treatment with bispecific monoclonal antibodies.
Experts on multiple myeloma